Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673555 · ClinicalTrials.gov registry record · Phase 1
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
A Phase 1 study of Anaemia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT01673555 is a Phase 1 study of Anaemia that has completed, run by GlaxoSmithKline. The registered enrollment target is 49 participants, below the 59-participant average among 3 other Anaemia trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01673555, a Phase 1 study of Anaemia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers. Healthy subjects will be evaluated using echocardiography to estimate PASP based on the velocity of the tricuspid regurgitant jet. Resting PASP will be assessed under normoxic (room air) conditions, as well as after 30 minutes' exposure to 15% O2 before, during, and after short-term treatment with GSK1278863.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK1278863
Study Locations (1)
Maryland
- GSK Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-05-15 |
| Est. Completion | 2012-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673555
The ClinicalTrials.gov registry entry for NCT01673555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 3 other Anaemia trials with a reported enrollment target (17% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anaemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01673555 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01673555 about?
NCT01673555 is a clinical study titled "Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers". This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers. Healthy subjects will be evaluated using echocardiography to estimate PASP based on the velocity of the tricuspid regurgitant jet. Resting PASP wi...
What is the current status of trial NCT01673555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-05-15. Estimated completion is 2012-11-19.
What conditions does trial NCT01673555 study?
This clinical trial studies the following conditions: Anaemia.
What interventions are being tested in trial NCT01673555?
The interventions under investigation include: Placebo (DRUG), GSK1278863 (DRUG).
Who is sponsoring clinical trial NCT01673555?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01673555 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects
COMPLETED · Phase 1
-
Daprodustat Hepatic Impairment Study
COMPLETED · Phase 1
-
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.